A Phase I Trial With Cohort Expansion of BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 20 Jan 2018 Status changed to discontinued.
- 20 Jan 2018 Final results assessing safety and efficacy presented at the 2018 Gastrointestinal Cancers Symposium
- 13 Oct 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.